Acquisition of Corthera, Inc.

Novartis AG

Our attorneys represented Novartis AG in connection with competition and regulatory approval aspects of its February 2010 acquisition of Corthera, Inc., a privately-held biopharmaceutical company engaged in the research and development of Relaxin, for US$120million, with Corthera’s shareholders being eligible for additional payments of up to US$500 million contingent upon successful development and commercial milestones. Our attorneys assisted the company in obtaining early termination of Federal Trade Commission review of the transaction.

Email Disclaimer